Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YPN-008
- Development stage
- Preclinical
- Lead developer
- Yungjin Pharm
- Modality
- Small Molecules
01
Overview
YPN-008 is an experimental drug candidate being developed by Yungjin Pharmaceutical for the treatment of Parkinson's disease. Currently in the discovery stage, the program is being developed in collaboration with Kanaph Therapeutics and Neurame. As a new chemical entity (NCE) within Yungjin's R&D pipeline, YPN-008 is part of a series of candidates aimed at addressing neurodegenerative and oncological conditions. Detailed information regarding its specific biological target and molecular mechanism of action has not yet been publicly disclosed.
Beyond the preview
Go deeper on YPN-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YPN-008.